Prostate cancer working group report

Mikio Namiki, Hideyuki Akaza, Sang Eun Lee, Jae Mann Song, Rainy Umbas, Liqun Zhou, Boon Cheok Lee, Christopher Cheng, Moon Kee Chung, Takashi Fukagai, Shiro Hinotsu, Shigeo Horie

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The incidence of prostate cancer, while still lower than in Western nations, is increasing rapidly in Asian countries due to a more westernized lifestyle. Prostate cancer mortality is declining in the USA, where most prostate cancers are diagnosed in the early stage. In contrast, the mortality rates of prostate cancer in Asian countries are expected to continue to increase, because the percentage of advanced-stage prostate cancers remains high. Therefore, early detection by prostate-specific antigen screening and a comprehensive strategy for cancer prevention are essential for Asian people. The exposure rate of prostatespecific antigen screening is very low in Asian countries. Increased prostate-specific antigen screening may reduce the mortality rate. The stances regarding population screening differ among countries. Urological associations should promote population screening. Reliable data from Asian countries are needed. The prostate cancer incidence is low in Asian countries, perhaps due to high soy consumption. Isoflavones may prevent prostate cancer in Asian countries, but that is not yet clear. A large, multinational study in Asia is needed to clarify whether or not isoflavone consumption shows efficacy in preventing prostate cancer. Clinical data suggest that hormonal therapy is more effective in Asians than in Westerners. Clinical guidelines should consider including hormonal therapy as one of the options for the treatment of localized prostate cancer. At the same time, effort should be made to decrease the adverse effects of each treatment. Collaborative studies on the treatment of prostate cancer should be carried out among Asian countries.

Original languageEnglish
Article numberhyq130
JournalJapanese Journal of Clinical Oncology
Volume40
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Sep 2010
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Isoflavones
Prostate-Specific Antigen
Mortality
Therapeutics
Incidence
Population
Life Style
Guidelines
Antigens
Neoplasms

Keywords

  • Cancer prevention
  • Isoflavone
  • Prostate cancer
  • PSA screening

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Namiki, M., Akaza, H., Lee, S. E., Song, J. M., Umbas, R., Zhou, L., ... Horie, S. (2010). Prostate cancer working group report. Japanese Journal of Clinical Oncology, 40(SUPPL. 1), [hyq130]. https://doi.org/10.1093/jjco/hyq130

Prostate cancer working group report. / Namiki, Mikio; Akaza, Hideyuki; Lee, Sang Eun; Song, Jae Mann; Umbas, Rainy; Zhou, Liqun; Lee, Boon Cheok; Cheng, Christopher; Chung, Moon Kee; Fukagai, Takashi; Hinotsu, Shiro; Horie, Shigeo.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. SUPPL. 1, hyq130, 09.2010.

Research output: Contribution to journalArticle

Namiki, M, Akaza, H, Lee, SE, Song, JM, Umbas, R, Zhou, L, Lee, BC, Cheng, C, Chung, MK, Fukagai, T, Hinotsu, S & Horie, S 2010, 'Prostate cancer working group report', Japanese Journal of Clinical Oncology, vol. 40, no. SUPPL. 1, hyq130. https://doi.org/10.1093/jjco/hyq130
Namiki M, Akaza H, Lee SE, Song JM, Umbas R, Zhou L et al. Prostate cancer working group report. Japanese Journal of Clinical Oncology. 2010 Sep;40(SUPPL. 1). hyq130. https://doi.org/10.1093/jjco/hyq130
Namiki, Mikio ; Akaza, Hideyuki ; Lee, Sang Eun ; Song, Jae Mann ; Umbas, Rainy ; Zhou, Liqun ; Lee, Boon Cheok ; Cheng, Christopher ; Chung, Moon Kee ; Fukagai, Takashi ; Hinotsu, Shiro ; Horie, Shigeo. / Prostate cancer working group report. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. SUPPL. 1.
@article{2630a82bce1943f989ecb0e9615eeb07,
title = "Prostate cancer working group report",
abstract = "The incidence of prostate cancer, while still lower than in Western nations, is increasing rapidly in Asian countries due to a more westernized lifestyle. Prostate cancer mortality is declining in the USA, where most prostate cancers are diagnosed in the early stage. In contrast, the mortality rates of prostate cancer in Asian countries are expected to continue to increase, because the percentage of advanced-stage prostate cancers remains high. Therefore, early detection by prostate-specific antigen screening and a comprehensive strategy for cancer prevention are essential for Asian people. The exposure rate of prostatespecific antigen screening is very low in Asian countries. Increased prostate-specific antigen screening may reduce the mortality rate. The stances regarding population screening differ among countries. Urological associations should promote population screening. Reliable data from Asian countries are needed. The prostate cancer incidence is low in Asian countries, perhaps due to high soy consumption. Isoflavones may prevent prostate cancer in Asian countries, but that is not yet clear. A large, multinational study in Asia is needed to clarify whether or not isoflavone consumption shows efficacy in preventing prostate cancer. Clinical data suggest that hormonal therapy is more effective in Asians than in Westerners. Clinical guidelines should consider including hormonal therapy as one of the options for the treatment of localized prostate cancer. At the same time, effort should be made to decrease the adverse effects of each treatment. Collaborative studies on the treatment of prostate cancer should be carried out among Asian countries.",
keywords = "Cancer prevention, Isoflavone, Prostate cancer, PSA screening",
author = "Mikio Namiki and Hideyuki Akaza and Lee, {Sang Eun} and Song, {Jae Mann} and Rainy Umbas and Liqun Zhou and Lee, {Boon Cheok} and Christopher Cheng and Chung, {Moon Kee} and Takashi Fukagai and Shiro Hinotsu and Shigeo Horie",
year = "2010",
month = "9",
doi = "10.1093/jjco/hyq130",
language = "English",
volume = "40",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Prostate cancer working group report

AU - Namiki, Mikio

AU - Akaza, Hideyuki

AU - Lee, Sang Eun

AU - Song, Jae Mann

AU - Umbas, Rainy

AU - Zhou, Liqun

AU - Lee, Boon Cheok

AU - Cheng, Christopher

AU - Chung, Moon Kee

AU - Fukagai, Takashi

AU - Hinotsu, Shiro

AU - Horie, Shigeo

PY - 2010/9

Y1 - 2010/9

N2 - The incidence of prostate cancer, while still lower than in Western nations, is increasing rapidly in Asian countries due to a more westernized lifestyle. Prostate cancer mortality is declining in the USA, where most prostate cancers are diagnosed in the early stage. In contrast, the mortality rates of prostate cancer in Asian countries are expected to continue to increase, because the percentage of advanced-stage prostate cancers remains high. Therefore, early detection by prostate-specific antigen screening and a comprehensive strategy for cancer prevention are essential for Asian people. The exposure rate of prostatespecific antigen screening is very low in Asian countries. Increased prostate-specific antigen screening may reduce the mortality rate. The stances regarding population screening differ among countries. Urological associations should promote population screening. Reliable data from Asian countries are needed. The prostate cancer incidence is low in Asian countries, perhaps due to high soy consumption. Isoflavones may prevent prostate cancer in Asian countries, but that is not yet clear. A large, multinational study in Asia is needed to clarify whether or not isoflavone consumption shows efficacy in preventing prostate cancer. Clinical data suggest that hormonal therapy is more effective in Asians than in Westerners. Clinical guidelines should consider including hormonal therapy as one of the options for the treatment of localized prostate cancer. At the same time, effort should be made to decrease the adverse effects of each treatment. Collaborative studies on the treatment of prostate cancer should be carried out among Asian countries.

AB - The incidence of prostate cancer, while still lower than in Western nations, is increasing rapidly in Asian countries due to a more westernized lifestyle. Prostate cancer mortality is declining in the USA, where most prostate cancers are diagnosed in the early stage. In contrast, the mortality rates of prostate cancer in Asian countries are expected to continue to increase, because the percentage of advanced-stage prostate cancers remains high. Therefore, early detection by prostate-specific antigen screening and a comprehensive strategy for cancer prevention are essential for Asian people. The exposure rate of prostatespecific antigen screening is very low in Asian countries. Increased prostate-specific antigen screening may reduce the mortality rate. The stances regarding population screening differ among countries. Urological associations should promote population screening. Reliable data from Asian countries are needed. The prostate cancer incidence is low in Asian countries, perhaps due to high soy consumption. Isoflavones may prevent prostate cancer in Asian countries, but that is not yet clear. A large, multinational study in Asia is needed to clarify whether or not isoflavone consumption shows efficacy in preventing prostate cancer. Clinical data suggest that hormonal therapy is more effective in Asians than in Westerners. Clinical guidelines should consider including hormonal therapy as one of the options for the treatment of localized prostate cancer. At the same time, effort should be made to decrease the adverse effects of each treatment. Collaborative studies on the treatment of prostate cancer should be carried out among Asian countries.

KW - Cancer prevention

KW - Isoflavone

KW - Prostate cancer

KW - PSA screening

UR - http://www.scopus.com/inward/record.url?scp=77957263902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957263902&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq130

DO - 10.1093/jjco/hyq130

M3 - Article

C2 - 20870924

AN - SCOPUS:77957263902

VL - 40

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - SUPPL. 1

M1 - hyq130

ER -